Walgreens Boots Alliance, Inc.
Walgreens Boots Alliance, Inc. (Form: 10-Q, Received: 07/06/2016 17:09:15)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended May 31, 2016

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______to _______

Commission File Number
001-36759
 
WALGREENS BOOTS ALLIANCE, INC.
 (Exact name of registrant as specified in its charter)
 
Delaware
 
47-1758322
(State of Incorporation)
 
(I.R.S. Employer Identification No.)

108 Wilmot Road, Deerfield, Illinois
 
60015
(Address of principal executive offices)
 
(Zip Code)

(847) 315-2500
(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes ☑       No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).   Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company.  See definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☑
Accelerated filer ☐
Non-accelerated filer ☐  (Do not check if a smaller reporting company)
Smaller reporting company ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐        No ☑

The number of shares outstanding of the registrant’s Common Stock, $.01 par value, as of June 30, 2016 was 1,082,317,487.
 


WALGREENS BOOTS ALLIANCE, INC.

FORM 10-Q FOR THE QUARTER ENDED MAY 31, 2016

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION

 
Item 1.
Consolidated Condensed Financial Statements (Unaudited)
   
a)
3
   
b)
4
   
c)
5
   
d)
6
   
e)
7
   
f)
8
 
Item 2.
31
 
Item 3.
52
 
Item 4.
52

PART II.  OTHER INFORMATION

 
Item 1.
53
 
Item 1A.
53
 
Item 2.
54
 
Item 6.
55
 
- 2 -

PART I. FINANCIAL INFORMATION
 
Item 1. Consolidated Condensed Financial Statements (Unaudited)

WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED BALANCE SHEETS
(UNAUDITED)
(In millions, except per share amounts)

   
May 31,
2016
   
August 31,
2015
 
Assets
           
Current Assets:
           
Cash and cash equivalents
 
$
3,291
   
$
3,000
 
Accounts receivable, net
   
6,508
     
6,849
 
Inventories
   
8,931
     
8,678
 
Other current assets
   
983
     
1,130
 
Total Current Assets
   
19,713
     
19,657
 
Non-Current Assets:
               
Property, plant and equipment, at cost, less accumulated depreciation and amortization
   
14,493
     
15,068
 
Goodwill
   
16,102
     
16,372
 
Intangible assets
   
11,556
     
12,351
 
Other non-current assets
   
5,469
     
5,334
 
Total Non-Current Assets
   
47,620
     
49,125
 
Total Assets
 
$
67,333
   
$
68,782
 
                 
Liabilities and Equity
               
Current Liabilities:
               
Short-term borrowings
 
$
374
   
$
1,068
 
Trade accounts payable
   
10,337
     
10,088
 
Accrued expenses and other liabilities
   
4,852
     
5,225
 
Income taxes
   
248
     
176
 
Total Current Liabilities
   
15,811
     
16,557
 
Non-Current Liabilities:
               
Long-term debt
   
13,151
     
13,315
 
Deferred income taxes
   
3,058
     
3,538
 
Other non-current liabilities
   
3,999
     
4,072
 
Total Non-Current Liabilities
   
20,208
     
20,925
 
Commitments and Contingencies (see Note 12)
               
Equity:
               
Preferred stock $.01 par value; authorized 32 million shares, none issued
   
-
     
-
 
Common stock $.01 par value; authorized 3.2 billion shares; issued 1,172,513,618 at May 31, 2016 and August 31, 2015
   
12
     
12
 
Paid-in capital
   
10,061
     
9,953
 
Employee stock loan receivable
   
(1
)
   
(2
)
Retained earnings
   
27,061
     
25,089
 
Accumulated other comprehensive loss
   
(1,277
)
   
(214
)
Treasury stock, at cost; 90,712,025 shares at May 31, 2016 and 82,603,274 at August 31, 2015
   
(4,975
)
   
(3,977
)
Total Walgreens Boots Alliance, Inc. Shareholders’ Equity
   
30,881
     
30,861
 
Noncontrolling interests
   
433
     
439
 
Total Equity
   
31,314
     
31,300
 
Total Liabilities and Equity
 
$
67,333
   
$
68,782
 

The accompanying Notes to Consolidated Condensed Financial Statements are an integral part of these Statements.
 
WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENT OF EQUITY
(UNAUDITED)
For the nine month period ended May 31, 2016
(In millions, except per share amounts)

   
Equity attributable to Walgreens Boots Alliance, Inc.
             
 
Common Stock
Shares
   
Common
Stock
 Amount
   
Treasury
 Stock
 Amount
   
Paid-In
Capital
   
Employee
Stock
Loan
Receivable
   
Accumulated
Other
Comprehensive
Loss
   
Retained
 Earnings
   
Noncontrolling
Interests
   
Total
Equity
 
August 31, 2015
   
1,089,910,344
   
$
12
   
$
(3,977
)
 
$
9,953
   
$
(2
)
 
$
(214
)
 
$
25,089
   
$
439
   
$
31,300
 
Net earnings
   
-
     
-
     
-
     
-
     
-
     
-
     
3,143
     
13
     
3,156
 
Other comprehensive income (loss), net of tax
   
-
     
-
     
-
     
-
     
-
     
(1,063
)
   
-
     
(27
)
   
(1,090
)
Dividends declared ($1.08 per share)
   
-
     
-
     
-
     
-
     
-
     
-
     
(1,171
)
   
-
     
(1,171
)
Treasury stock purchases
   
(13,815,558
)
   
-
     
(1,152
)
   
-
     
-
     
-
     
-
     
-
     
(1,152
)
Employee stock purchase and option plans
   
5,706,807
     
-
     
154
     
21
     
-
     
-
     
-
     
-
     
175
 
Employee stock loan receivable
   
-
     
-
     
-
     
-
     
1
     
-
     
-
     
-
     
1
 
Stock-based compensation
   
-
     
-
     
-
     
87
     
-
     
-
     
-
     
-
     
87
 
Other
   
-
     
-
     
-
     
-
     
-
     
-
     
-
     
8
     
8
 
May 31, 2016
   
1,081,801,593
   
$
12
   
$
(4,975
)
 
$
10,061
   
$
(1
)
 
$
(1,277
)
 
$
27,061
   
$
433
   
$
31,314
 

The accompanying Notes to Consolidated Condensed Financial Statements are an integral part of these Statements.
 
WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS
(UNAUDITED)
(In millions, except per share amounts)

   
Three Months Ended
   
Nine Months Ended
 
   
May 31, 2016
   
May 31, 2015
   
May 31, 2016
   
May 31, 2015
 
                         
Net sales
 
$
29,498
   
$
28,795
   
$
88,715
   
$
74,922
 
Cost of sales
   
22,001
     
21,314
     
65,772
     
55,263
 
Gross Profit
   
7,497
     
7,481
     
22,943
     
19,659
 
                                 
Selling, general and administrative expenses
   
5,967
     
6,080
     
18,085
     
16,142
 
Equity earnings in AmerisourceBergen
   
3
     
-
     
3
     
-
 
Equity earnings in Alliance Boots
   
-
     
-
     
-
     
315
 
Operating Income
   
1,533
     
1,401
     
4,861
     
3,832
 
                                 
Gain on previously held equity interest
   
-
     
-
     
-
     
706
 
Other income (expense)
   
28
     
461
     
(525
)
   
1,164
 
Earnings Before Interest and Income Tax Provision
   
1,561
     
1,862
     
4,336
     
5,702
 
                                 
Interest expense, net
   
147
     
151
     
425
     
350
 
Earnings Before Income Tax Provision
   
1,414
     
1,711
     
3,911
     
5,352
 
Income tax provision
   
322
     
408
     
790
     
1,120
 
Post tax earnings from equity method investments
   
15
     
7
     
35
     
15
 
Net Earnings
   
1,107
     
1,310
     
3,156
     
4,247
 
Net earnings attributable to noncontrolling interests
   
4
     
8
     
13
     
53
 
Net Earnings Attributable to Walgreens Boots Alliance, Inc.
 
$
1,103
   
$
1,302
   
$
3,143
   
$
4,194
 
                                 
Net earnings per common share attributable to Walgreens Boots Alliance, Inc. – basic
 
$
1.02
   
$
1.19
   
$
2.90
   
$
4.08
 
Net earnings per common share attributable to Walgreens Boots Alliance, Inc. – diluted
 
$
1.01
   
$
1.18
   
$
2.88
   
$
4.04
 
                                 
Dividends declared per share
 
$
0.3600
   
$
0.3375
   
$
1.0800
   
$
1.0125
 
                                 
Average shares outstanding
   
1,080.8
     
1,091.4
     
1,083.3
     
1,026.9
 
Dilutive effect of stock options
   
7.4
     
11.0
     
8.4
     
10.8
 
Average diluted shares
   
1,088.2
     
1,102.4
     
1,091.7
     
1,037.7
 

The accompanying Notes to Consolidated Condensed Financial Statements are an integral part of these Statements.
 
WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
(In millions)

   
Three Months Ended
   
Nine Months Ended
 
   
May 31, 2016
   
May 31, 2015
   
May 31, 2016
   
May 31, 2015
 
Comprehensive Income
                       
                         
Net Earnings
 
$
1,107
   
$
1,310
   
$
3,156
   
$
4,247
 
                                 
Other comprehensive income (loss), net of tax:
                               
Pension/postretirement obligations
   
3
     
(2
)
   
4
     
(11
)
Unrealized gain (loss) on cash flow hedges
   
-
     
-
     
2
     
(12
)
Unrecognized gain (loss) on available-for-sale investments
   
(172
)
   
74
     
(259
)
   
263
 
Share of other comprehensive income of Alliance Boots
   
-
     
-
     
-
     
113
 
Currency translation adjustments
   
769
     
(149
)
   
(837
)
   
(639
)
Total Other Comprehensive Income (Loss)
   
600
     
(77
)
   
(1,090
)
   
(286
)
Total Comprehensive Income
   
1,707
     
1,233
     
2,066
     
3,961
 
                                 
Comprehensive income (loss) attributable to noncontrolling interests
   
12
     
4
     
(15
)
   
44
 
Comprehensive Income Attributable to Walgreens Boots Alliance, Inc.
 
$
1,695
   
$
1,229
   
$
2,081
   
$
3,917
 

The accompanying Notes to Consolidated Condensed Financial Statements are an integral part of these Statements.
 
WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(In millions)

   
Nine Months Ended
 
   
May 31, 2016
   
May 31, 2015
 
             
Cash Flows from Operating Activities :
           
Net earnings
 
$
3,156
   
$
4,247
 
Adjustments to reconcile net earnings to net cash provided by operating activities -
               
Depreciation and amortization
   
1,271
     
1,264
 
Change in fair value of warrants and related amortization
   
845
     
(1,313
)
Gain on previously held equity interest
   
-
     
(706
)
Deferred income taxes
   
(250
)
   
240
 
Stock compensation expense
   
87
     
86
 
Equity earnings from equity method investments
   
(38
)
   
(315
)
Other
   
(14
)
   
624
 
Changes in operating assets and liabilities -
               
Accounts receivable, net
   
8
     
(273
)
Inventories
   
(481
)
   
679
 
Other current assets
   
21
     
54
 
Trade accounts payable
   
686
     
19
 
Accrued expenses and other liabilities
   
(247
)
   
(152
)
Income taxes
   
135
     
(179
)
Other non-current assets and liabilities
   
10
     
(116
)
Net cash provided by operating activities
   
5,189
     
4,159
 
                 
Cash Flows from Investing Activities :
               
Additions to property, plant and equipment
   
(904
)
   
(890
)
Proceeds from sale leaseback transactions
   
60
     
867
 
Proceeds related to sale of business
   
68
     
814
 
Proceeds from sale of other assets
   
116
     
71
 
Alliance Boots acquisition, net of cash received
   
-
     
(4,461
)
Other business and intangible asset acquisitions, net of cash received
   
(115
)
   
(112
)
Investment in AmerisourceBergen
   
(1,169
)
   
-
 
Other
   
(17
)
   
(173
)
Net cash used for investing activities
   
(1,961
)
   
(3,884
)
                 
Cash Flows from Financing Activities :
               
Payments of short-term borrowings, net
   
(658
)
   
(251
)
Proceeds from issuance of long-term debt
   
-
     
12,279
 
Payments of long-term debt
   
(31
)
   
(8,582
)
Stock purchases
   
(1,152
)
   
(831
)
Proceeds related to employee stock plans
   
175
     
400
 
Cash dividends paid
   
(1,174
)
   
(1,013
)
Other
   
(54
)
   
(380
)
Net cash (used for) provided by financing activities
   
(2,894
)
   
1,622
 
                 
Effect of exchange rate changes on cash and cash equivalents
   
(43
)
   
(94
)
                 
Changes in Cash and Cash Equivalents :
               
Net increase in cash and cash equivalents
   
291
     
1,803
 
Cash and cash equivalents at beginning of period
   
3,000
     
2,646
 
Cash and cash equivalents at end of period
 
$
3,291
   
$
4,449
 

The accompanying Notes to Consolidated Condensed Financial Statements are an integral part of these Statements.
 
WALGREENS BOOTS ALLIANCE, INC. AND SUBSIDIARIES
NOTES TO FINANCIAL STATEMENTS
(UNAUDITED)

Note 1. Organization
Walgreens Boots Alliance, Inc. (“Walgreens Boots Alliance”) and subsidiaries are a global pharmacy-led health and wellbeing enterprise. Its operations are conducted through three reportable segments (Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale). See Note 18, Segment Reporting for further information.

On December 31, 2014, Walgreens Boots Alliance became the successor of Walgreen Co. (“Walgreens”) pursuant to a merger designed to effect a reorganization of Walgreens into a holding company structure (the “Reorganization”). Pursuant to the Reorganization, Walgreens became a wholly-owned subsidiary of Walgreens Boots Alliance, a Delaware corporation formed for the purposes of the Reorganization, and each issued and outstanding share of Walgreens common stock converted on a one-to-one basis into Walgreens Boots Alliance common stock. References to the “Company” refer to Walgreens Boots Alliance and its subsidiaries from and after the effective time of the Reorganization on December 31, 2014 and, prior to that time, to the predecessor registrant Walgreens and its subsidiaries, except as otherwise indicated or the context otherwise requires.

On December 31, 2014, following the completion of the Reorganization, Walgreens Boots Alliance completed the acquisition of the remaining 55% of Alliance Boots GmbH (“Alliance Boots”) that Walgreens did not previously own (the “Second Step Transaction”) in exchange for £3.133 billion in cash and approximately 144.3 million shares of Walgreens Boots Alliance common stock. Alliance Boots became a consolidated subsidiary and ceased being accounted for under the equity method immediately upon completion of the Second Step Transaction. For financial reporting and accounting purposes, Walgreens Boots Alliance was the acquirer of Alliance Boots. The consolidated financial statements (and other data) reflect the results of operations and financial position of Walgreens and its subsidiaries for periods prior to December 31, 2014 and of Walgreens Boots Alliance and its subsidiaries for periods from and after the effective time of the Reorganization on December 31, 2014.

As part of the Second Step Transaction, the Company acquired the remaining 27.5% noncontrolling interest in Walgreens Boots Alliance Development GmbH (“WBAD”), a global sourcing enterprise established by the Company and Alliance Boots. The Company already owned a 50% direct ownership in WBAD and indirectly owned an additional ownership interest through its previous 45% investment in Alliance Boots, representing a direct and indirect economic interest of 72.5%. The Company’s acquisition of the remaining 27.5% effective ownership in WBAD as part of the Second Step Transaction was accounted for as an equity transaction as it has historically been consolidated by the Company. On January 1, 2015, WBAD Holdings Limited sold 320 common shares of WBAD, representing approximately 5% of the equity interests in WBAD, to Alliance Healthcare Italia Distribuzione S.p.A. (“AHID”), which is not a member of the Company’s consolidated group. Under certain circumstances, AHID has the right to put, and WBAD Holdings Limited has the right to call, the 320 common shares of WBAD currently owned by AHID for a purchase price of $100,000.

Note 2. Accounting Policies
Basis of Presentation
The consolidated condensed financial statements of Walgreens Boots Alliance included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission regarding interim financial reporting. The consolidated condensed financial statements include all subsidiaries in which the Company holds a controlling interest. Investments in less than majority-owned entities in which the Company does not have a controlling interest, but does have significant influence, are accounted for as equity method investments. All intercompany transactions have been eliminated.

The Consolidated Condensed Balance Sheet as of May 31, 2016, the Consolidated Condensed Statements of Equity and the Consolidated Condensed Statements of Cash Flows for the nine month period ended May 31, 2016, and the Consolidated Condensed Statements of Earnings and the Consolidated Condensed Statements of Comprehensive Income for the three month and nine month periods ended May 31, 2016 and May 31, 2015, have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The financial statements have not been audited. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. These unaudited consolidated condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto included in the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2015.
 
In the opinion of the Company, the unaudited consolidated condensed financial statements for the interim periods presented include all adjustments (consisting only of normal recurring adjustments) necessary to present a fair statement of the results for such interim periods. Because of the acquisition of Alliance Boots, influence of certain holidays, seasonality, foreign currency rates, changes in vendor, payer and customer relationships and terms and other factors on the Company’s operations, net earnings for any interim period may not be comparable to the same interim period in previous years or indicative of net earnings for the full fiscal year. In addition, with respect to the Company’s Retail Pharmacy USA segment, the positive impact on gross profit margins and gross profit dollars typically has been significant in the first several months after a generic version of a drug is first allowed to compete with the branded version, which is generally referred to as a “generic conversion.” In any given year, the number of major brand name drugs that undergo a conversion from branded to generic status can increase or decrease, which can have a significant impact on Retail Pharmacy USA segment’s sales, gross profit margins and gross profit dollars.

The preparation of financial statements requires management to use judgment in the application of accounting policies, which are all in accordance with GAAP, including making estimates and assumptions. The Company bases its estimates on the information available at the time, its experience and other assumptions believed to be reasonable under the circumstances. Adjustments may be made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Actual results may differ. For a discussion of the Company’s significant accounting policies, please see the Walgreens Boots Alliance Annual Report on Form 10-K for the fiscal year ended August 31, 2015.

Note 3. Restructuring
On April 8, 2015, the Walgreens Boots Alliance Board of Directors approved a plan to implement a new restructuring program (the “Cost Transformation Program”) as part of an initiative to reduce costs and increase operating efficiencies. The Cost Transformation Program implemented and built on the cost-reduction initiative previously announced by the Company on August 6, 2014 and included plans to close approximately 200 stores across the U.S.; reorganize corporate and field operations; drive operating efficiencies; and streamline information technology and other functions. The actions under the Cost Transformation Program focus primarily on Retail Pharmacy USA segment, but includes activities from all segments and are expected to be substantially complete by the end of the Company’s 2017 fiscal year. The Company estimates that it will recognize cumulative pre-tax charges to its GAAP financial results of between $1.6 billion and $1.8 billion, including costs associated with lease obligations and other real estate payments, asset impairments and employee termination and other business transition and exit costs. The Company expects to incur pre-tax charges of between $525 million and $600 million for real estate costs, including lease obligations (net of estimated sublease income); between $650 million and $725 million for asset impairment charges relating primarily to asset write-offs from store closures, information technology, inventory and other non-operational real estate asset write-offs; and between $425 million and $475 million for employee severance and other business transition and exit costs. The Company incurred pre-tax charges of $73 million and $191 million related to the Cost Transformation Program during the three and nine months ended May 31, 2016.   The Company incurred pre-tax charges of $160 million related to the Cost Transformation Program in the three and nine months ended May 31, 2015. From inception through May 31, 2016, the Company incurred pre-tax charges of $733 million ($296 million related to asset impairment charges, $254 million in real estate costs and $183 million in severance and other business transition and exit costs) related to the Cost Transformation Program. All charges related to the Cost Transformation Program have been recorded within selling, general and administrative expenses. As the program is implemented, the restructuring charges will be recognized as the costs are incurred over time in accordance with GAAP.

In March 2014, the Walgreens Board of Directors approved a plan to close underperforming stores in efforts to optimize and focus resources within the Retail Pharmacy USA segment in a manner intended to increase stockholder value. As of August 31, 2015, this plan was completed and no additional charges related to the plan are expected. There were no charges incurred in the three month period ended May 31, 2015. For the nine months ended May 31, 2015, the Company incurred pre-tax charges of $17 million, which were primarily related to lease termination costs. All charges related to this plan have been recorded within selling, general and administrative expenses.

Restructuring costs by segment are as follows (in millions):

   
Retail Pharmacy
             
Three Months Ended May 31, 2016
 
USA
   
International
   
Pharmaceutical
Wholesale
   
Consolidated
 
Real estate costs
 
$
-
   
$
-
   
$
-
   
$
-
 
Asset impairments
   
48
     
-
     
-
     
48
 
Severance and other business transition and exit costs
   
12
     
6
     
7
     
25
 
Total restructuring costs
 
$
60
   
$
6
   
$
7
   
$
73
 
 
Three Months Ended May 31, 2015
                               
Real estate costs
 
$
24
   
$
-
   
$
-
   
$
24
 
Asset impairments
   
102
     
-
     
-
     
102
 
Severance and other business transition and exit costs
   
25
     
9
     
-
     
34
 
Total restructuring costs
 
$
151
   
$
9
   
$
-
   
$
160
 
 
   
Retail Pharmacy
             
Nine Months Ended May 31, 2016
 
USA
   
International
   
Pharmaceutical
Wholesale
   
Consolidated
 
Real estate costs
 
$
52
   
$
-
   
$
-
   
$
52
 
Asset impairments
   
73
     
-
     
-
     
73
 
Severance and other business transition and exit costs
   
45
     
14
     
7
     
66
 
Total restructuring costs
 
$
170
   
$
14
   
$
7
   
$
191
 
 
Nine Months Ended May 31, 2015
                       
Real estate costs
 
$
41
   
$
-
   
$
-
   
$
41
 
Asset impairments
   
102
     
-
     
-
     
102
 
Severance and other business transition and exit costs
   
25
     
9
     
-
     
34
 
Total restructuring costs
 
$
168
   
$
9
   
$
-
   
$
177
 

Note 4. Operating Leases
Initial terms for leased premises in the U.S. are typically 15 to 25 years, followed by additional terms containing renewal options at five-year intervals, and may include rent escalation clauses. Non-U.S. leases are typically for shorter terms and may include cancellation clauses or renewal options. The commencement date of all lease terms is the earlier of the date the Company becomes legally obligated to make rent payments or the date the Company has the right to control the property. The Company recognizes rent expense on a straight-line basis over the term of the lease. In addition to minimum fixed rentals, some leases provide for contingent rentals based upon a portion of sales.

The Company provides for future costs related to closed locations. The liability is based on the present value of future rent obligations and other related costs (net of estimated sublease rent) to the first lease option date. During the three and nine months ended May 31, 2016, the Company recorded charges of $16 million and $91 million, respectively, for facilities that were closed or relocated under long-term leases, including stores closed through the Company’s restructuring activities. This compares to $34 million for the three months ended and $60 million for the nine months ended May 31, 2015. Charges are reported in selling, general and administrative expenses on the Consolidated Condensed Statements of Earnings.

The changes in reserve for facility closings and related lease termination charges include the following (in millions):

   
Nine Month
Period Ended
May 31,
2016
   
Twelve Month
Period Ended
August 31,
2015
 
Balance – beginning of period
 
$
446
   
$
257
 
Provision for present value of non-cancellable lease payments on closed facilities
   
89
     
231
 
Assumptions about future sublease income, terminations and changes in interest rates
   
(19
)
   
(6
)
Interest accretion
   
21
     
27
 
Liability assumed through acquisition of Alliance Boots
   
-
     
13
 
Cash payments, net of sublease income
   
(81
)
   
(76
)
Balance – end of period
 
$
456
   
$
446
 
 
The Company remains secondarily liable on 76 leases.  For leases on which the Company remains secondarily liable, the maximum potential undiscounted future payments are $343 million at May 31, 2016. Lease option dates vary, with some lease terms extending up to 2039.

Note 5. Equity Method Investments
Equity method investments as of May 31, 2016 and August 31, 2015 were as follows (in millions, except percentages):

   
May 31, 2016
   
August 31, 2015
 
   
Carrying
Value
   
Ownership
Percentage
   
Carrying
Value
   
Ownership
Percentage
 
AmerisourceBergen
 
$
2,936
     
16
%
 
$
NA    
NA
 
Other
 
 
1,227
     
12% - 50
%
 
 
1,242
     
12% - 50
%
Total
 
$
4,163
           
$
1,242
         

AmerisourceBergen Investment
On March 18, 2016, the Company exercised warrants to purchase 22,696,912 shares of AmerisourceBergen Corporation (“AmerisourceBergen”) common stock at an exercise price of $51.50 per share for an aggregate exercise price payment of $1.17 billion. As of May 31, 2016, the Company owned 34,157,955 AmerisourceBergen common shares representing approximately 16% of the outstanding AmerisourceBergen common stock and accounts for its equity investment in AmerisourceBergen using the equity method of accounting, subject to a two-month reporting lag, with the net earnings attributable to the Company’s investment being classified within the operating income of its Pharmaceutical Wholesale segment. The Company continues to hold additional warrants to purchase an additional 22,696,912 shares of AmerisourceBergen common stock, which the Company has the right to exercise beginning in March 2017. See Note 10, Financial Instruments for further information. Due to the March 18, 2016 effective date and the two-month reporting lag, our results for the three and nine month periods ended May 31, 2016 include thirteen days of equity method income.  Equity earnings from AmerisourceBergen is reported as a separate line in the Consolidated Condensed Statements of Earnings.
 
Other Investments
The Company’s other equity method investments include its investments in Guangzhou Pharmaceuticals Corporation and Nanjing Pharmaceutical Corporation Limited, the Company’s pharmaceutical wholesale investments in China; and the equity method investment retained through the sale of a majority interest in Option Care Inc. in fiscal 2015. The Company reported $15 million and $35 million of post-tax equity earnings in other equity method investments for the three and nine month periods ended May 31, 2016, respectively, in the Consolidated Condensed Statements of Earnings. The Company reported $7 million and $15 million of post-tax equity earnings from equity method investments other than Alliance Boots for the three and nine month periods ended May 31, 2015.

Equity method investments of the Company are recorded within other non-current assets on the Consolidated Condensed Balance Sheets.

Note 6. Available-for-Sale Investments
A summary of the cost and fair value of available-for-sale securities, with gross unrealized gains and losses, is as follows (in millions):

   
May 31, 2016
 
   
Amortized
cost basis
 
Gross
unrealized
gains
 
Gross
unrealized
losses
 
Fair value
 
Other investments
   
37
   
-
   $  
(2
)
 
35
 
 
   
August 31, 2015
 
   
Amortized
cost basis
 
Gross
unrealized
gains
 
Gross
unrealized
losses
 
Fair value
 
AmerisourceBergen common stock
   
$
717
   
$
430
   
$
-
   
$
1,147
 
Other investments
     
37
     
-
     
(1
)
   
36
 
Total available-for-sale investments
   
$
754
   
$
430
   
$
(1
)
 
$
1,183
 

On March 18, 2016, the Company exercised warrants to purchase 22,696,912 shares of AmerisourceBergen common stock at an exercise price of $51.50 per share, which resulted in a change in method of accounting for the Company’s investment to the equity method of accounting. In conjunction with the change to the equity method of accounting, the Company recognized $268 million of Other Comprehensive Income to Other income (expense) within the Consolidated Condensed Statement of Earnings. See Note 5, Equity Method Investments, Note 10, Financial Instruments and Note 19, Recent Accounting Pronouncements for further information.
 
For the three and nine month periods ended May 31, 2016, there were $1 million and $4 million, respectively, of available-for-sale securities sold. There were no sales of available-for-sale investments for the three and nine month periods ended May 31, 2015.

The Company’s other available-for-sale investments are classified within other current assets in the Consolidated Condensed Balance Sheets.

Note 7. Acquisitions
The aggregate purchase price of all business and intangible assets acquired, net of cash received, was $115 million for the nine month period ended May 31, 2016. These acquisitions included an international beauty brand and prescription files resulting in an increase of $21 million to goodwill and $88 million to intangible assets. Operating results of the businesses acquired have been included in the Consolidated Condensed Statements of Earnings from their respective acquisition dates forward. Pro forma results of the Company, assuming all of the other acquisitions had occurred at the beginning of each period presented, would not be materially different from the results reported.

Note 8. Goodwill and Other Intangible Assets
Changes in the carrying amount of goodwill by reportable segment consist of the following activity (in millions):

   
Retail Pharmacy
USA
   
Retail Pharmacy
International
   
Pharmaceutical
Wholesale
   
Total
 
August 31, 2015
 
$
8,940
   
$
3,898
   
$
3,534
   
$
16,372
 
Acquisitions
   
-
     
21
     
-
     
21
 
Other (1)
   
(4
)
   
(5
)
   
13
     
4
 
Currency translation adjustments
   
-
     
(151
)
   
(144
)
   
(295
)
May 31, 2016
 
$
8,936
   
$
3,763
   
$
3,403
   
$
16,102
 

(1) Other primarily represents immaterial purchase accounting adjustments for prior year Company acquisitions.

The carrying amount and accumulated amortization of intangible assets   consist of the following (in millions):

   
May 31, 2016
   
August 31, 2015
 
Gross Amortizable Intangible Assets
           
Customer relationships
 
$
1,368
   
$
1,409
 
Purchased prescription files
   
925
     
885
 
Trade names and trademarks
   
681
     
675
 
Loyalty card holders
   
661
     
730
 
Favorable lease interests
   
456
     
440
 
Non-compete agreements
   
161
     
154
 
Purchasing and payer contracts
   
94
     
94
 
Total gross amortizable intangible assets
   
4,346
     
4,387
 
                 
Accumulated amortization
               
Customer relationships
   
223
     
132
 
Purchased prescription files
   
569
     
470
 
Trade names and trademarks
   
129
     
83
 
Loyalty card holders
   
41
     
41
 
Favorable lease interests
   
258
     
207
 
Non-compete agreements
   
113
     
92
 
Purchasing and payer contracts
   
70
     
65
 
Total accumulated amortization
   
1,403
     
1,090
 
Total amortizable intangible assets, net
 
$
2,943
   
$
3,297
 
                 
Indefinite Lived Intangible Assets
               
Trade names and trademarks
 
$
6,271
   
$
6,590
 
Pharmacy licenses
   
2,342
     
2,464
 
Total indefinite lived intangible assets
 
$
8,613
   
$
9,054
 
                 
Total intangible assets, net
 
$
11,556
   
$
12,351
 
 
Amortization expense for intangible assets was $104 million and $320 million for the three and nine months ended May 31, 2016, respectively, and $104 million and $368 million for the three and nine months ended May 31, 2015, respectively.

Estimated annual amortization expense for intangible assets recorded at May 31, 2016 is as follows (in millions):

   
2016
   
2017
   
2018
   
2019
   
2020
 
Estimated annual amortization expense
 
$
426
   
$
381
   
$
338
   
$
301
   
$
254
 

Note 9. Short-Term Borrowings and Long-Term Debt
Short-term borrowings and long-term debt consist of the following (all amounts are presented in millions of U.S. dollars and debt issuances are denominated in U.S. dollars, unless otherwise noted):

   
May 31, 2016
   
August 31, 2015
 
Short-Term Borrowings ( 1 )
           
Unsecured variable rate notes due 2016
 
$
-
   
$
747
 
Other (2)
   
374
     
321
 
Total short-term borrowings
 
$
374
   
$
1,068
 
 
Long-Term Debt (1)
           
Unsecured Pound Sterling variable rate term loan due 2019 (3)
 
$
2,121
   
$
2,229
 
1.750% unsecured notes due 2017
   
747
     
746
 
5.250% unsecured notes due 2019 (4)
   
252
     
250
 
2.700% unsecured notes due 2019
   
1,244
     
1,243
 
2.875% unsecured Pound Sterling notes due 2020 (3)
   
582
     
612
 
3.300% unsecured notes due 2021
   
1,242
     
1,241
 
3.100% unsecured notes due 2022
   
1,193
     
1,193
 
3.800% unsecured notes due 2024
   
1,986
     
1,985
 
3.600% unsecured Pound Sterling notes due 2025 (3)
   
437
     
459
 
2.125% unsecured Euro notes due 2026 (5)
   
832
     
836
 
4.500% unsecured notes due 2034
   
494
     
494
 
4.400% unsecured notes due 2042
   
492
     
492
 
4.800% unsecured notes due 2044
   
1,486
     
1,491
 
Other (6)
   
43
     
44
 
Total long-term debt
 
$
13,151
   
$
13,315
 

(1) All notes are presented net of unamortized discount and debt issuance costs, where applicable.
(2) Other short-term borrowings represent a mix of fixed and variable rate borrowings with various maturities and working capital facilities denominated in various foreign currencies including bank overdrafts.
(3) Pound Sterling denominated notes are translated at the spot rates of $1.46 and $1.54 to one British Pound Sterling at May 31, 2016 and August 31, 2015, respectively.
 
(4) Also includes interest rate swap fair market value adjustments. See Note 11, Fair Value Measurements for additional fair value disclosures.
(5) Euro denominated notes are translated at the spot rate of $1.12 to one Euro at May 31, 2016 and August 31, 2015.
(6) Other long-term debt represents a mix of fixed and variable rate borrowings in various foreign currencies with various maturities.
 
On June 1, 2016, Walgreens Boots Alliance received net proceeds (after deducting underwriting discounts and estimated offering expenses) of $5,957 million from a public offering of fixed rate notes with varying maturities and interest rates. See Note 20, Subsequent Events for further information.

$8.0 Billion Note Issuance
On November 18, 2014, Walgreens Boots Alliance received net proceeds (after deducting underwriting discounts and estimated offering expenses) of $7.9 billion from a public offering of notes with varying maturities and interest rates, the majority of which are fixed rate. The notes are unsecured, unsubordinated debt obligations of Walgreens Boots Alliance and rank equally in right of payment with all other unsecured and unsubordinated indebtedness of Walgreens Boots Alliance from time to time outstanding. The notes were fully and unconditionally guaranteed on an unsecured and unsubordinated basis by Walgreens until August 10, 2015, when such guarantees were unconditionally released and discharged . Total issuance costs relating to the notes, including underwriting discounts and estimated offering expenses, were $44 million. The Company repaid the $750 million variable rate notes on their May 18, 2016 maturity date.

The following table summarizes each tranche of outstanding notes as of May 31, 2016:

Notes Issued
(in millions)
 
 
Maturity Date
 
Interest Rate
 
Interest Payment Dates
$
750
 
November 17, 2017
Fixed 1.750%
May 17 and November 17; commencing on May 17, 2015
 
1,250
 
November 18, 2019
Fixed 2.700%
May 18 and November 18; commencing on May 18, 2015
 
1,250
 
November 18, 2021
Fixed 3.300%
May 18 and November 18; commencing on May 18, 2015
 
2,000
 
November 18, 2024
Fixed 3.800%
May 18 and November 18; commencing on May 18, 2015
 
500
 
November 18, 2034
Fixed 4.500%
May 18 and November 18; commencing on May 18, 2015
 
1,500
 
November 18, 2044
Fixed 4.800%
May 18 and November 18; commencing on May 18, 2015
$
7,250
         

The fair value of the notes outstanding as of May 31, 2016 was $7.4 billion. Fair value for these notes was determined based upon quoted market pri ces.

Redemption Option
Walgreens Boots Alliance may redeem (a) the notes due 2017, at any time in whole or from time to time in part, (b) the notes due 2019, at any time prior to October 18, 2019 in whole or from time to time prior to October 18, 2019 in part, (c) the notes due 2021, at any time prior to September 18, 2021 in whole or from time to time prior to September 18, 2021 in part, (d) the notes due 2024, at any time prior to August 18, 2024 in whole or from time to time prior to August 18, 2024 in part, (e) the notes due 2034, at any time prior to May 18, 2034 in whole or from time to time prior to May 18, 2034 in part, and (f) the notes due 2044, at any time prior to May 18, 2044 in whole or from time to time prior to May 18, 2044 in part, in each case, at Walgreens Boots Alliance ’s option for the sum of accrued and unpaid interest plus a redemption price equal to the greater of:

(1) 100% of the principal amount of the fixed rate notes being redeemed; and
 
(2) the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued as of the redemption date), discounted to the redemption date on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate (as defined in the applicable series of notes), plus 15 basis points for the notes due 2017, 15 basis points for the notes due 2019, 20 basis points for the notes due 2021, 20 basis points for the notes due 2024, 20 basis points for the notes due 2034 and 25 basis points for the notes due 2044.

In addition, at any time on or after October 18, 2019 with respect to the notes due 2019, September 18, 2021 with respect to the notes due 2021, August 18, 2024 with respect to the notes due 2024, May 18, 2034 with respect to the notes due 2034, or May 18, 2044 with respect to the notes due 2044, Walgreens Boots Alliance may redeem some or all of the applicable series of fixed rate notes at its option, at a redemption price equal to 100% of the principal amount of the applicable fixed rate notes being redeemed, plus accrued and unpaid interest on the fixed rate notes being redeemed to, but excluding, the redemption date.
 
Change in Control
If Walgreens Boots Alliance experiences a change of control triggering event, unless Walgreens Boots Alliance has exercised its option to redeem the fixed rate notes or has defeased the notes as described in the indenture, Walgreens Boots Alliance will be required to offer payment of cash equal to 101% of the aggregate principal amount of the notes plus accrued and unpaid interest.

£700 Million and €750 Million Notes Issuance
On November 20, 2014, Walgreens Boots Alliance issued three series of debt securities denominated in Euros and Pound Sterling in a public offering, each with varying maturities and interest rates. Interest on all notes is payable annually on November 20, commencing on November 20, 2015. The notes are unsecured, unsubordinated debt obligations of Walgreens Boots Alliance and rank equally in right of payment with all other unsecured and unsubordinated indebtedness of Walgreens Boots Alliance from time to time outstanding. The notes were fully and unconditionally guaranteed on an unsecured and unsubordinated basis by Walgreens until August 10, 2015, when such guarantees were unconditionally released and discharged. Total issuance costs relating to the notes, including underwriting discounts and estimated offering expenses, were $11 million.

The following table details each tranche of Euro and Pound Sterling outstanding notes as of May 31, 2016:

Notes Issued (in millions)
 
Maturity Date
Interest Rate
Euro Notes:
      
750
 
November 20, 2026
Fixed 2.125%
           
Pound Sterling Notes:
      
£
400
 
November 20, 2020
Fixed 2.875%
 
300
 
November 20, 2025
Fixed 3.600%
£
700
      

The fair value of the notes as of May 31, 2016 was $1.9 billion. Fair value for these notes was determined based upon quoted market prices.

Redemption Option
Walgreens Boots Alliance may redeem (a) the Euro notes, at any time prior to August 20, 2026, in whole or, from time to time prior to August 20, 2026, in part, (b) the Pound Sterling notes due 2020, at any time prior to October 20, 2020, in whole or, from time to time prior to October 20, 2020, in part, and (c) the Pound Sterling notes due 2025, at any time prior to August 20, 2025, in whole or, from time to time prior to August 20, 2025, in part, in each case, at Walgreens Boots Alliance’s option for the sum of accrued and unpaid interest plus at a redemption price equal to the greater of:

(1)
100% of the principal amount of the notes to be redeemed; and

(2) the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued as of the redemption date), discounted to the redemption date on an annual basis at the applicable Comparable Government Bond Rate (as defined in the applicable series of notes), plus 20 basis points for the Euro notes, 20 basis points for the Pound Sterling notes due 2020 and 20 basis points for Pound Sterling the notes due 2025.

In addition, at any time on or after August 20, 2026 with respect to the Euro notes, October 20, 2020 with respect to the Pound Sterling notes due 2020, or August 20, 2025 with respect to the Pound Sterling notes due 2025, Walgreens Boots Alliance may redeem some or all of the applicable series of notes at its option at a redemption price equal to 100% of the principal amount of the applicable notes to be redeemed plus, in every case, accrued and unpaid interest on the notes to be redeemed to, but excluding, the redemption date.

Change in Control
If Walgreens Boots Alliance experiences a change of control triggering event, unless Walgreens Boots Alliance has exercised its option to redeem the fixed rate notes or has defeased the notes as described in the indenture, Walgreens Boots Alliance will be required to offer payment of cash equal to 101% of the aggregate principal amount of the notes plus accrued and unpaid interest.
 
$4.0 Billion Note Issuance
On September 13, 2012, Walgreens obtained net proceeds from a public offering of $4.0 billion of notes with varying maturities and interest rates, the majority of which, at issuance, were fixed rate. The notes are unsecured senior debt obligations and rank equally with all other unsecured and unsubordinated indebtedness of Walgreens. On December 31, 2014, Walgreens Boots Alliance fully and unconditionally guaranteed the outstanding notes on an unsecured and unsubordinated basis. The guarantee, for so long as it is in place, is an unsecured, unsubordinated debt obligation of Walgreens Boots Alliance and will rank equally in right of payment with all other unsecured and unsubordinated indebtedness of Walgreens Boots Alliance. Total issuance costs relating to the notes, including underwriting discounts and fees, were $26 million. On August 10, 2015, the 1.8000% fixed rate notes due September 15, 2017 in the aggregate principal amount of $1.0 billion were redeemed in full. The redemption price was equal to 101.677% of the aggregate principal amount of the notes redeemed, plus accrued interest thereon to, but excluding, the redemption date, and included a $17 million make whole premium, which was recorded as interest expense on the Company’s Consolidated Statements of Earnings. Additionally, the Company repaid the $750 million 1.000% fixed rate notes on their March 13, 2015 maturity date and the $550 million variable rate notes on their March 13, 2014 maturity date.

The following table details each tranche of outstanding notes as of May 31, 2016:
 
Notes Issued
(in millions)
 
Maturity Date
Interest Rate
Interest Payment Dates
$
1,200
 
September 15, 2022
Fixed 3.100%
March 15 and September 15; commencing on March 15, 2013
 
500
 
September 15, 2042
Fixed 4.400%
March 15 and September 15; commencing on March 15, 2013
$
1,700
         

The fair value of the notes outstanding as of May 31, 2016 was $1.7 billion. Fair value for these notes was determined based upon quoted market prices.

Redemption Option and Change in Control
Walgreens may redeem the fixed rate notes at its option, at any time in whole, or from time to time in part, at a redemption price equal to the greater of: (a) 100% of the principal amount of the notes being redeemed; and (b) the sum of the present values of the remaining scheduled payments of principal and interest thereon (not including any portion of such payments of interest accrued as of the date of redemption), discounted to the date of redemption on a semiannual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate (as defined in the applicable series of notes), plus 12 basis points for the notes due 2015, 22 basis points for the notes due 2022 and 25 basis points for the notes due 2042. If a change of control triggering event occurs, Walgreens will be required, unless it has exercised its right to redeem the notes, to offer to purchase the notes at a purchase price equal to 101% of their principal amount, plus accrued and unpaid interest, if any, on the notes repurchased to the date of repurchase.

$1.0 Billion Note Issuance
On January 13, 2009, Walgreens issued notes totaling $1.0 billion bearing an interest rate of 5.250% paid semiannually in arrears on January 15 and July 15 of each year, beginning on July 15, 2009. The notes will mature on January 15, 2019. The notes are unsecured senior debt obligations and rank equally with all other unsecured senior indebtedness of Walgreens. On December 31, 2014, Walgreens Boots Alliance fully and unconditionally guaranteed the outstanding notes on an unsecured and unsubordinated basis. The guarantee, for so long as it is in place, is an unsecured, unsubordinated debt obligation of Walgreens Boots Alliance and will rank equally in right of payment with all other unsecured and unsubordinated indebtedness of Walgreens Boots Alliance. The notes are not convertible or exchangeable. Total issuance costs relating to this offering, including underwriting discounts and fees, were $8 million. On August 10, 2015, $750 million aggregate principal amount of the notes were redeemed. The redemption price was equal to 111.734% of the aggregate principal amount of the notes redeemed plus accrued interest thereon to, but excluding, the redemption date; and included a $88 million make whole premium, which was recorded as interest expense on the Company’s Consolidated Statements of Earnings. The partial redemption of the notes resulted in $250 million aggregate principal amount of the notes remaining outstanding. The fair value of the notes outstanding as of May 31, 2016 was $269 million. Fair value for these notes was determined based upon quoted market prices.

Redemption Option and Change in Control
Walgreens may redeem the notes, at any time in whole or from time to time in part, at its option at a redemption price equal to the greater of: (a) 100% of the principal amount of the notes to be redeemed; or (b) the sum of the present values of the remaining scheduled payments of principal and interest, discounted to the date of redemption on a semiannual basis at the Treasury Rate (as defined in the applicable series of notes), plus 45 basis points, plus accrued interest on the notes to be redeemed to, but excluding, the date of redemption. If a change of control triggering event occurs, unless Walgreens has exercised its option to redeem the notes, it will be required to offer to repurchase the notes at a purchase price equal to 101% of the principal amount of the notes plus accrued and unpaid interest to the date of redemption.
 
Other Borrowings
The Company periodically borrows under its commercial paper program and may borrow under it in future periods. There were no commercial paper borrowings outstanding as of May 31, 2016 or May 31, 2015, respectively. The Company had weighted average daily short-term borrowings of $18 million of commercial paper outstanding at a weighted average interest rate of 0.66% for the nine month period ended May 31, 2016. The Company had average daily short-term borrowings of $110 million of commercial paper outstanding at a weighted average interest rate of 0.52% for the nine month period ended May 31, 2015.

2014 Term Loan Agreement and Revolving Credit Agreement

On November 10, 2014, Walgreens Boots Alliance and Walgreens entered into a term loan credit agreement (the “Term Loan Agreement”), which provided Walgreens Boots Alliance and Walgreens with the ability to borrow up to £1.45 billion on an unsecured basis. Borrowings under the Term Loan Agreement bear interest at a fluctuating rate per annum equal to the reserve adjusted LIBOR plus an applicable margin based on the Company’s credit ratings. As of May 31, 2016, Walgreens Boots Alliance had borrowed £1.45 billion ($2.1 billion at the May 31, 2016 spot rate of $1.46 to £1) under the Term Loan Agreement. The fair value of the Term Loan Agreement as of May 31, 2016 was $2.1 billion. Fair value of the borrowings under the Term Loan Agreement was determined based upon quoted market prices.

On November 10, 2014, Walgreens Boots Alliance and Walgreens entered into a five-year unsecured, multicurrency revolving credit agreement (the “Revolving Credit Agreement”), replacing prior Walgreens agreements dated July 20, 2011 and July 23, 2012. This unsecured revolving credit agreement initially totaled $2.25 billion, of which $375 million was available for the issuance of letters of credit. On December 29, 2014, upon the affirmative vote of the majority of common shares of Walgreens represented and entitled to vote at the Walgreens special meeting of shareholders to approve the issuance of the shares necessary to complete the Second Step Transaction, the available credit increased to $3.0 billion, of which $500 million is available for the issuance of letters of credit. The issuance of letters of credit reduces the aggregate amount otherwise available under the Revolving Credit Agreement for the making of revolving loans. Borrowings under the Revolving Credit Agreement bear interest at a fluctuating rate per annum equal to, at Walgreens Boots Alliance’s option, the alternate base rate or the reserve adjusted LIBOR, in each case, plus an applicable margin calculated based on the Company’s credit ratings. As of May 31, 2016, there were no borrowings or letters of credit issued pursuant to the Revolving Credit Agreement.

Total upfront fees related to the Term Loan Agreement and Revolving Credit Agreement were $14 million. The Company pays a facility fee to the financing banks to keep these lines of credit active.

In accordance with the terms of each of the Term Loan Agreement and the Revolving Credit Agreement, Walgreens guaranteed the punctual payment when due, whether at stated maturity, by acceleration or otherwise, of all of Walgreens Boots Alliance’s obligations under the Term Loan Agreement and Revolving Credit Agreement, as applicable until August 10, 2015, when such guarantees automatically terminated, without penalty to Walgreens or Walgreens Boots Alliance, and the obligations of Walgreens thereunder were unconditionally released and discharged.

On December 19, 2014, Walgreens Boots Alliance and Walgreens entered into a Revolving Credit Agreement (as amended, the “364-Day Credit Agreement”) with the lenders party thereto. The 364-Day Credit Agreement was a $750 million, 364-day unsecured, multicurrency revolving facility. On July 9, 2015, Walgreens Boots Alliance amended the 364-Day Credit Agreement to remove Walgreens as a borrower thereunder, eliminate Walgreens’ guarantee of all obligations of Walgreens Boots Alliance thereunder and make certain conforming changes to effectuate those modifications, including modifications and deletions of certain definitions and cross-references. On December 17, 2015, the Company terminated the 364-Day Credit Agreement. The 364-Day Credit Agreement remained undrawn as of the date of termination and would have matured on December 30, 2015.

The Term Loan Agreement, Revolving Credit Agreement and the 364-Day Revolving Credit Agreement each contain or contained a covenant to maintain, as of the last day of each fiscal quarter, a ratio of consolidated debt to total capitalization not to exceed 0.60 to 1.00, as well as other customary restrictive covenants.
 
2015 Bridge Credit Agreement and Term Loan Credit Agreement

On October 27, 2015, the Company entered into an Agreement and Plan of Merger with Rite Aid Corporation (“Rite Aid”) and Victoria Merger Sub, Inc., a wholly-owned subsidiary of the Company (the “Merger Agreement”). In connection with the Merger Agreement, the Company entered into a bridge facility commitment letter (as amended and restated as of November 19, 2015, the “Commitment Letter”), with UBS Securities LLC and UBS AG, Stamford Branch for a $12.8 billion senior unsecured bridge facility.
 
On December 18, 2015, Walgreens Boots Alliance entered into a Bridge Term Loan Credit Agreement with the lenders party thereto and UBS AG, Stamford Branch, as administrative agent (as amended on January 20, 2016, the “Bridge Credit Agreement”) and a Term Loan Credit Agreement with the lenders party thereto and Bank of America, N.A., as administrative agent (as amended on January 20, 2016, the “Term Loan Credit Agreement” and together with the Bridge Credit Agreement, the “2015 Credit Agreements”). The Commitment Letter and the commitments contemplated thereby terminated upon Walgreens Boots Alliance entering into the 2015 Credit Agreements.

The Bridge Credit Agreement is a 364-day unsecured bridge term loan facility. The aggregate commitments of all lenders under the Bridge Credit Agreement are equal to $7.8 billion, provided that Walgreens Boots Alliance may increase the commitments under the Bridge Credit Agreement at any time prior to the funding of the loans thereunder by up to $2.0 billion, subject to obtaining commitments from existing lenders and/or new lenders selected by Walgreens Boots Alliance and reasonably acceptable to the administrative agent. Walgreens Boots Alliance can extend up to $3.0 billion of the loans under the Bridge Credit Agreement for an additional 90-day period if desired. As of May 31, 2016, there were no borrowings under the Bridge Credit Agreement. As a result of the issuance of the notes and receipt of proceeds therefrom as described above, on June 1, 2016, Walgreens Boots Alliance reduced its commitment under the Bridge Credit Agreement by $5,956,593,000. See Note 20, Subsequent Events for further information.

The Term Loan Credit Agreement is a two-tranche unsecured term loan facility, with the first tranche maturing three years after the earlier of the funding date and October 27, 2016, and the second tranche maturing five years after the earlier of the funding date and October 27, 2016. The aggregate commitments of all lenders under the Term Loan Credit Agreement are equal to $5.0 billion. As of May 31, 2016, there were no borrowings under the Term Loan Credit Agreement.

Walgreens Boots Alliance will be the borrower under each of the 2015 Credit Agreements. The ability of Walgreens Boots Alliance to request the making of loans under each of the 2015 Credit Agreements is subject to the satisfaction (or waiver) of certain conditions set forth therein and will terminate upon the occurrence of certain events set forth therein. Borrowings under each of the 2015 Credit Agreements will bear interest at a fluctuating rate per annum equal to, at Walgreens Boots Alliance’s option, the alternate base rate or the reserve adjusted Eurocurrency rate, in each case, plus an applicable margin calculated based on Walgreens Boots Alliance’s credit ratings. Upfront fees paid to date in connection with the 2015 Credit Agreements totaled $30 million. A maximum of a further $5 million in upfront fees is payable prior to, or at funding, subject to certain conditions. In addition, Walgreens Boots Alliance will also pay to the lenders under each of the 2015 Credit Agreements certain customary fees, including a ticking fee based on the aggregate outstanding commitments of the lenders under the applicable 2015 Credit Agreement starting at 90 days after signing. Each of the 2015 Credit Agreements contains a covenant to maintain, as of the last day of each fiscal quarter, a ratio of consolidated debt to total capitalization not to exceed 0.60 to 1.00, as well as other customary restrictive covenants, which restrictive covenants shall not be in effect until the funding of the loans under the applicable 2015 Credit Agreement.

Note 10. Financial Instruments
The Company uses derivative instruments to manage its exposure to interest rate and foreign currency exchange risks.

The notional amounts, fair value and balance sheet presentation of derivative instruments outstanding as of May 31, 2016, excluding warrants which are presented separately in this footnote, were as follows (in millions):

   
Notional (1)
   
Fair Value
 
Location in Consolidated
Condensed Balance Sheets
Derivatives designated as fair value hedges :
               
Interest rate swaps
 
$
250
   
$
4
 
Other non-current assets
Derivatives not designated as hedges :
                   
Foreign currency forwards
   
1,082
     
17
 
Other current assets
Basis swap
   
2
     
1
 
Other current liabilities

(1) Amounts are presented in U.S. dollar equivalents.

The notional amounts, fair value and balance sheet presentation of derivative instruments outstanding as of August 31, 2015, excluding warrants which are presented separately in this footnote, are as follows (in millions):

   
Notional (1)
   
Fair Value
 
Location in Consolidated
Condensed Balance Sheets
Derivatives designated as fair value hedges :
               
Interest rate swaps
 
$
250
   
$
2
 
Other non-current assets
Derivatives not designated as hedges :
                   
Foreign currency forwards
   
1,205
     
34
 
Other current assets
Foreign currency forwards
   
495
     
9
 
Other current liabilities
Basis swap
   
1
     
-
 
Other current assets
 
(1) Amounts are presented in U.S. dollar equivalents.
 
The Company uses interest rate swaps to manage the interest rate exposure associated with some of its fixed-rate borrowings and designates them as fair value hedges. The Company uses forward starting interest rate swaps to hedge its interest rate exposure of some of its anticipated debt issuances and designates them as cash flow hedges.

The Company utilizes foreign currency forward contracts and other foreign currency derivatives to hedge significant committed and highly probable future transactions and cash flows denominated in currencies other than the functional currency of the Company or its subsidiaries. The Company has significant non-US dollar denominated net investments and uses foreign currency denominated financial instruments, specifically foreign currency derivatives and foreign currency denominated debt, to hedge its foreign currency risk.

Fair Value Hedges
The Company entered into a series of interest rate swaps, converting $750 million of its 5.250% fixed rate notes to a floating interest rate based on the six month LIBOR in arrears plus a constant spread and an interest rate swap converting $250 million of its 5.250% fixed rate notes to a floating interest rate based on the one-month LIBOR in arrears plus a constant spread. All swap termination dates coincide with the notes maturity date, January 15, 2019. These swaps were designated as fair value hedges. On August 10, 2015, the Company terminated $500 million of the six month LIBOR in arrears swaps and all of the one-month LIBOR in arrears swaps in connection with the repayment of the associated debt as described in Note 9, Short-Term Borrowings and Long-Term Debt .

The gains and losses due to changes in fair value on the swaps and on the hedged notes attributable to interest rate risk were recognized as follows (in millions):

      
Three Months Ended
   
Nine Months Ended
 
Location in Consolidated
Condensed Statements of
Earnings
 
May 31,
2016
   
May 31,
2015
   
May 31,
2016
   
May 31,
2015
 
Interest rate swaps
Interest expense, net
 
$
1
   
$
7
   
$
(2
)
 
$
(13
)
Notes
Interest expense, net
   
(2
)
   
(7
)
   
1
     
13
 

The changes in fair value of the Company’s debt that was swapped from fixed to variable rate and designated as fair value hedges are included in short-term and long-term debt on the Consolidated Condensed Balance Sheets (see Note 9, Short-Term Borrowings and Long-Term Debt). At May 31, 2016 and August 31, 2015, the cumulative fair value adjustments resulted in an increase in long-term debt of $3 million and $1 million, respectively. No material gains or losses were recorded from ineffectiveness during the three and nine months ended May 31, 2016 and May 31, 2015.

Derivatives not Designated as Hedges
The Company enters into derivative transactions that are not designated as accounting hedges. These derivative instruments are economic hedges of interest rate and foreign currency risks. The gains and losses due to changes in fair value of these derivative instruments were recognized in earnings as follows (in millions):

     
Three Months Ended
   
Nine Months Ended
 
Location in Consolidated
Condensed Statements of
Earnings
 
May 31, 2016
   
May 31, 2015
   
May 31, 2016
   
May 31, 2015
 
Interest rate swaps
Interest expense, net
 
$
-
   
$
-
   
$
-
   
$
1
 
Foreign currency forwards
Selling, general and administrative expenses
   
24
     
49
     
(1)
     
38
 
Second Step Transaction foreign currency forwards
Other income (expense)
   
-
     
-
     
-
     
(166
)
Foreign currency forwards
Other income (expense)
   
4
     
7
     
37
     
17
 
 
Warrants
On March 18, 2016, the Company exercised warrants to purchase 22,696,912 shares of AmerisourceBergen common stock at an exercise price of $51.50 per share for an aggregate exercise price payment of $1.17 billion. See Note 5, Equity Method Investments, Note 6, Available-for-Sale Investments and Note 19, Recent Accounting Pronouncements for further information.

As of May 31, 2016, the Company holds additional warrants to purchase up to 22,696,912 shares of AmerisourceBergen common stock at an exercise price of $52.50 per share, exercisable during a six month period beginning in March 2017.

The Company reports the warrants at fair value. The fair value and balance sheet presentation of the warrants was as follows (in millions):

Location in Consolidated
 Condensed Balance Sheets
 
May 31,
2016
   
August 31,
2015
 
Asset derivatives not designated as hedges:
             
Warrants
Other non-current assets
 
$
498
   
$
2,140
 

The gains and losses due to changes in fair value of the warrants recognized in earnings were as follows (in millions):

      
Three Months Ended
   
Nine Months Ended
 
Location in Consolidated
Condensed Statements of Earnings
 
May 31, 2016
   
May 31, 2015
   
May 31, 2016
   
May 31, 2015
 
Warrants
Other income (expense)
 
$
(268
)
 
$
449
   
$
(862
)
 
$
1,298
 

Derivatives Credit Risk
Counterparties to derivative financial instruments expose the Company to credit-related losses in the event of counterparty nonperformance, and the Company regularly monitors the credit worthiness of each counterparty.

Derivatives Offsetting
The Company does not offset the fair value amounts of derivative instruments subject to master netting agreements in the Consolidated Condensed Balance Sheets.

Note 11. Fair Value Measurements
The Company measures certain assets and liabilities in accordance with ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value as the price that would be received for an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. In addition, it establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels:

Level 1 - Quoted prices in active markets that are accessible at the measurement date for identical assets and liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
Level 2 - Observable inputs other than quoted prices in active markets.
Level 3 - Unobservable inputs for which there is little or no market data available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

Assets and liabilities measured at fair value on a recurring basis were as follows (in millions):

   
May 31, 2016
   
Level 1
   
Level 2
   
Level 3
 
Assets :
                       
Restricted cash (1)
 
$
174
   
$
174
   
$
-
   
$
-
 
Money market funds (2)
   
2,363
     
2,363
     
-
     
-
 
Available-for-sale investments (3)
   
35
     
35
     
-
     
-
 
Interest rate swaps (4)
   
4
     
-
     
4
     
-
 
Foreign currency forwards (5)
   
17
     
-
     
17
     
-
 
Warrants (6)
   
498
     
-
     
498
     
-
 
Liabilities :
                               
Basis swaps (5)
   
1
     
-
     
1
     
-
 

   
August 31, 2015
   
Level 1
   
Level 2
   
Level 3
 
Assets :
                       
Restricted cash (1)
 
$
184
   
$
184
   
$
-
   
$
-
 
Money market funds (2)
   
2,043
     
2,043
     
-
     
-
 
Available-for-sale investments (3)
   
1,183
     
1,183
     
-
     
-
 
Interest rate swaps (4)
   
2
     
-
     
2
     
-
 
Foreign currency forwards (5)
   
34
     
-
     
34
     
-
 
Warrants (6)
   
2,140
     
-
     
2,140
     
-
 
Liabilities :
                               
Foreign currency forwards (5)
   
9
     
-
     
9
     
-
 

(1) Restricted cash consists of deposits restricted under agency agreements and cash restricted by law and other obligations.
(2) Money market funds are valued at the closing price reported by the fund sponsor.
(3) Fair values of quoted investments are based on current bid prices as of the balance sheet dates. See Note 6, Available-for-Sale Investments for additional information.
(4) The fair value of interest rate swaps is calculated by discounting the estimated cash flows received and paid based on the applicable observable yield curves. See Note 10, Financial Instruments for additional information.
(5) The fair value of basis swaps and forward currency contracts is estimated by discounting the difference between the contractual forward price and the current available forward price for the residual maturity of the contract using observable market rates.
(6)
Warrants were valued using the contingent claims option pricing method . Key assumptions used in the valuation include risk-free interest rates using constant maturity treasury rates; the dividend yield for AmerisourceBergen’s common stock; AmerisourceBergen’s common stock price at the valuation date; AmerisourceBergen’s equity volatility; the number of shares of AmerisourceBergen’s common stock outstanding; the number of AmerisourceBergen employee stock options and the exercise price; and the details specific to the warrants.

There were no transfers between levels for the three and nine month periods ended May 31, 2016 and May 31, 2015, respectively.

The Company reports its debt instruments under the guidance of ASC Topic 825, Financial Instruments, which requires disclosure of the fair value of the Company’s debt in the footnotes to the consolidated financial statements. Unless otherwise noted, the fair value for all notes was determined based upon quoted market prices and therefore categorized as Level 1. See Note 9, Short-Term Borrowings and Long-Term Debt for further information. The carrying values of accounts receivable and trade accounts payable approximated their respective fair values due to their short-term nature.

Note 12. Commitments and Contingencies
The Company is involved in legal proceedings and is subject to investigations, inspections, audits, inquiries and similar actions by governmental authorities, arising in the normal course of the Company’s business, including the matters described below. Legal proceedings, in general, and securities and class action litigation, in particular, can be expensive and disruptive. Some of these suits may purport or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Company is also involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property and other matters. Gain contingencies, if any, are recognized when they are realized. The results of legal proceedings are often uncertain and difficult to predict, and the costs incurred in litigation can be substantial, regardless of the outcome. The Company believes that its defenses and assertions in pending legal proceedings have merit, and does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company’s consolidated financial position. However, substantial unanticipated verdicts, fines and rulings do sometimes occur. As a result, the Company could from time to time incur judgments, enter into settlements or revise its expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid.
 
On a quarterly basis, the Company assesses its liabilities and contingencies for outstanding legal proceedings and reserves are established on a case-by-case basis for those legal claims for which management concludes that it is probable that a loss will be incurred and that the amount of such loss can be reasonably estimated. Substantially all of these contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. With respect to litigation and other legal proceedings where the Company has determined that a loss is reasonably possible, the Company is unable to estimate the amount or range of reasonably possible loss in excess of amounts reserved due to the inherent difficulty of predicting the outcome of and uncertainties regarding such litigation and legal proceedings. The Company’s assessments are based on estimates and assumptions that have been deemed reasonable by management, but that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause the Company to change those estimates and assumptions. Therefore, it is possible that an unfavorable resolution of one or more pending litigation or other contingencies could have a material adverse effect on the Company’s consolidated financial statements in a future fiscal period. Management’s assessment of current litigation and other legal proceedings, including the corresponding accruals, could change because of the discovery of facts with respect to legal actions or other proceedings pending against the Company which are not presently known. Adverse rulings or determinations by judges, juries, governmental authorities or other parties could also result in changes to management’s assessment of current liabilities and contingencies. Accordingly, the ultimate costs of resolving these claims may be substantially higher or lower than the amounts reserved.

On December 5 and 12, 2014, putative shareholders filed class actions in federal court in the Northern District of Illinois against the Walgreens Board of Directors, Walgreen Co., and Walgreens Boots Alliance, Inc. arising out of the Company’s definitive proxy statement/prospectus filed with the SEC in connection with the special meeting of Walgreens shareholders on December 29, 2014. The actions asserted claims that the definitive proxy statement/prospectus was false or misleading in various respects. On December 23, 2014, solely to avoid the costs, risks and uncertainties inherent in litigation, and without admitting any liability or wrongdoing, Walgreens entered into a memorandum of understanding with the plaintiffs in both actions, pursuant to which Walgreens made certain supplemental disclosures. The proposed settlement was subject to, among other things, court approval. On July 8, 2015, the Court preliminarily approved the settlement, and on November 20, 2015, the Court entered an order of final approval of the settlement. On December 17, 2015, a purported class member who had objected to the settlement appealed the Court’s order. The appeal was docketed with the United States Court of Appeals for the Seventh Circuit. Oral argument was held on June 2, 2016.

On December 29, 2014, a putative shareholder filed a derivative action in federal court in the Northern District of Illinois against certain current and former directors and officers of Walgreen Co., and Walgreen Co. as a nominal defendant, arising out of certain public statements the Company made regarding its former fiscal 2016 goals. The action asserts claims for breach of fiduciary duty, waste and unjust enrichment. On April 10, 2015, the defendants filed a motion to dismiss. On May 18, 2015, the case was stayed in light of the securities class action that was filed on April 10, 2015, which is described below.

On April 10, 2015, a putative shareholder filed a securities class action in federal court in the Northern District of Illinois against Walgreen Co. and certain former officers of Walgreen Co. The action asserts claims for violation of the federal securities laws arising out of certain public statements the Company made regarding its former fiscal 2016 goals. On June 16, 2015, the Court entered an order appointing a lead plaintiff. Pursuant to the Court’s order, lead plaintiff filed an amended complaint on August 17, 2015, and defendants moved to dismiss the amended complaint on October 16, 2015. Lead plaintiff filed a response to the motion to dismiss on December 22, 2015, and defendants filed a reply in support of the motion on February 5, 2016.

As of May 31, 2016, the Company was aware of ten putative class action lawsuits (the “Rite Aid actions”) filed by purported Rite Aid stockholders against Rite Aid and its board of directors, Walgreens Boots Alliance and Victoria Merger Sub, Inc. for claims arising out of the transactions contemplated by the Merger Agreement (the “Rite Aid Transactions”). Eight of the Rite Aid actions were filed in the Court of Chancery of the State of Delaware (the “Delaware actions”), one Rite Aid action was filed in the State of Pennsylvania in the Court of Common Pleas of Cumberland County (the “Pennsylvania action”), and one Rite Aid action was filed in the United States District Court for the Middle District of Pennsylvania (the “federal action”). The Delaware actions and the Pennsylvania action primarily allege that the Rite Aid board of directors breached its fiduciary duties in connection with the Rite Aid Transactions by, among other things, agreeing to an unfair and inadequate price, agreeing to deal protection devices that preclude other bidders from making successful competing offers for Rite Aid, and failing to disclose all allegedly material information concerning the proposed merger; and also allege that Walgreens Boots Alliance and Victoria Merger Sub, Inc. aided and abetted these alleged breaches of fiduciary duty. The federal action alleges, among other things, that Rite Aid and its board of directors disseminated an allegedly false and misleading proxy statement in connection with the Rite Aid Transactions. The Delaware actions were consolidated, and plaintiffs filed a motion for expedited proceedings and a motion for preliminary injunction seeking to enjoin the Rite Aid shareholder vote on the Rite Aid Transactions. The plaintiffs in the federal action also filed a motion for preliminary injunction seeking to enjoin the same Rite Aid shareholder vote. All such motions were denied, and the Rite Aid shareholders approved the Rite Aid Transactions at a special meeting on February 4, 2016. On April 15, 2016, the plaintiffs in the Delaware actions agreed to a settlement in principle related to this matter for an immaterial amount. In the Pennsylvania action, plaintiffs agreed to stay the litigation until after the Rite Aid Transactions have closed.
 
Note 13. Retirement Benefits
The Company sponsors several retirement plans, including defined benefit plans, defined contribution plans and a postretirement health plan. The Company uses an August 31 annual measurement date for its pension plans.

Defined Benefit Pension Plans (non-US plans)
The principal defined benefit pension plan is the Boots Pension Plan, which covers certain employees in the United Kingdom (the “Boots Plan”). The Boots Plan is a funded final salary defined benefit plan providing pensions and death benefits to members. The Boots Plan was closed to future accrual effective July 1, 2010, with pensions calculated based on salaries up until that date. The Boots Plan is governed by a trustee board, which is independent of the Company. The plan is subject to a full funding actuarial valuation on a triennial basis. The Company also has two smaller defined benefit pension plans in the United Kingdom, both of which were closed to future accruals effective July 1, 2010.   Other defined benefit pension plans include smaller plans in Germany and France.

The obligation related to the Company’s pension plans was acquired as a result of the Second Step Transaction . The pension costs presented for 2015 represent the costs for the period from December 31, 2014 through May 31, 2015. Prior to December 31, 2014, Alliance Boots was accounted for as an equity method investee and as such, pension costs for fiscal 2015 prior to the date of the Second Step Transaction were reflected within Equity earnings in Alliance Boots on the Consolidated Condensed Statement of Earnings.

Components of net periodic pension costs for the defined benefit pension plans (in millions):

   
Three Months Ended
   
Nine Months Ended
 
   
May 31, 2016
   
May 31, 2015
   
May 31, 2016
   
May 31, 2015
 
Service costs
 
$
1
   
$
2
   
$
3
   
$
3
 
Interest costs
   
77
     
79
     
236
     
132
 
Expected returns on plan assets
   
(62
)
   
(65
)
   
(189
)
   
(108
)
Settlements
   
-
     
(2
)
   
-
     
(1
)
Total net periodic pension costs
 
$
16
   
$
14
   
$
50
   
$
26
 

The Company made cash contributions to its defined benefit pension plans of $71 million for the nine month period ended May 31, 2016, which primarily related to committed funded payments. The Company does not expect to make further contributions to its defined benefit pension plans in fiscal 2016.

Defined Contribution Plans
The principal retirement plan for U.S. employees is the Walgreen Profit-Sharing Retirement Trust, to which both the Company and participating employees contribute. The Company’s contribution, which has historically related to adjusted FIFO earnings before interest and taxes and a portion of which is in the form of a guaranteed match, is determined annually at the discretion of the Walgreens Boots Alliance Board of Directors (or Compensation Committee thereof). The profit-sharing provision was an expense of $58 million and $169 million for the three and nine months ended May 31, 2016, respectively, compared to a benefit of $64 million for the three months and expense of $118 million for the nine months ended May 31, 2015, respectively.

The Company also has a contract based defined contribution arrangement, the Alliance Boots Retirement Savings Plan, to which both the Company and participating employees contribute. The obligation related to the Alliance Boots Retirement Savings Plan was acquired as a result of the Second Step Transaction. The cost recognized in the Consolidated Condensed Statements of Earnings for the three and nine month periods ended May 31, 2016 was $33 million and $102 million, respectively compared to $57 million in the prior year three and nine month periods. Prior to December 31, 2014, Alliance Boots was accounted for as an equity method investee and as such, such costs for fiscal 2015 prior to the date of the Second Step Transaction were reflected within Equity earnings in Alliance Boots on the Consolidated Condensed Statement of Earnings.

Postretirement Healthcare Plan
The Company provides certain health insurance benefits to retired U.S. employees who meet eligibility requirements, including age, years of service and date of hire. The costs of these benefits are accrued over the service life of the employee. The Company’s postretirement health benefit plan is not funded.
 
Components of net periodic benefit cost for the postretirement health benefit plan (in millions):

   
Three Months Ended
   
Nine Months Ended
 
   
May 31, 2016
   
May 31, 2015
   
May 31, 2016
   
May 31, 2015
 
Service cost
 
$
3
   
$
3
   
$
8
   
$
8
 
Interest cost
   
4
     
5
     
14
     
13
 
Amortization of actuarial loss
   
5
     
4
     
14
     
14
 
Amortization of prior service cost
   
(7
)
   
(6
)
   
(21
)
   
(18
)
Total postretirement benefit cost
 
$
5
   
$
6
   
$
15
   
$
17
 

Note 14. Earnings Per Share
The dilutive effect of outstanding stock options on earnings per share is calculated using the treasury stock method. Stock options are anti-dilutive and excluded from the earnings per share calculation if the exercise price exceeds the average market price of the common shares. There were 2.8 million outstanding options to purchase common shares that were anti-dilutive and excluded from the third quarter earnings per share calculation as of May 31, 2016 compared to no outstanding options as of May 31, 2015. Anti-dilutive shares excluded from the year to date earnings per share calculation were 2.4 million compared to 3.3 million for the periods ending May 31, 2016 and May 31, 2015, respectively.

Note 15. Depreciation and Amortization
The Company has recorded the following depreciation and amortization expense in the Consolidated Condensed Statements of Earnings (in millions):

   
Three Months Ended
   
Nine Months Ended
 
   
May 31, 2016
   
May 31, 2015
   
May 31, 2016
   
May 31, 2015
 
Depreciation expense
 
$
353
   
$
339
   
$
997
   
$
906
 
Intangible asset and other amortization
   
94
     
99
     
274
     
358
 
Total depreciation and amortization expense
 
$
447
   
$
438
   
$
1,271
   
$
1,264
 

The depreciation and amortization expense presented for 2015 include Alliance Boots costs for the period from December 31, 2014 through May 31, 2015. Prior to December 31, 2014, Alliance Boots was accounted for as an equity method investee and as such, depreciation and amortization expense were included for fiscal 2015 prior to the date of the Second Step Transaction within Equity earnings in Alliance Boots.

Note 16. Supplemental Cash Flow Disclosures
Cash interest paid was $512 million and $305 million in the nine months ended May 31, 2016 and May 31, 2015, respectively. Cash paid for income taxes was $812 million and $961 million in the nine months ended May 31, 2016 and May 31, 2015, respectively.

Note 17. Accumulated Other Comprehensive Income (Loss)
The following is a summary of net changes in accumulated other comprehensive income by component and net of tax for the three and nine months ended May 31, 2016 and May 31, 2015 (in millions):

   
Pension/Post-
retirement
 Obligations
   
Unrecognized
 Gain (Loss) on
Available-for-Sale
Investments
   
Unrealized
 Gain (Loss) on
 Cash Flow
Hedges
   
Currency
Translation
Adjustments
   
Total
 
Balance at February 29, 2016
 
$
30
   
$
172
   
$
(38
)
 
$
(2,032
)
 
$
(1,868
)
Other comprehensive income (loss) before reclassification adjustments
   
5
     
(6
)
   
-
     
762
     
761
 
Amounts reclassified from accumulated OCI
   
-
     
(268
)
   
1
     
(2
)
   
(269
)
Tax benefit (provision)
   
(2
)
   
102
     
(1
)
   
-
     
99
 
Net other comprehensive income (loss)
 
$
3
   
$
(172
)
 
$
-
   
$
760
   
$
591
 
Balance at May 31, 2016
 
$
33
   
$
-
   
$
(38
)
 
$
(1,272
)
 
$
(1,277
)
 
 
Pension/Post-
retirement
Obligations
   
Unrecognized
Gain (Loss) on
Available-for-Sale
Investments
   
Unrealized
Gain (Loss) on
Cash Flow
Hedges
   
Currency
Translation
Adjustments
   
Total
 
Balance at August 31, 2015
 
$
29
   
$
259
   
$
(40
)
 
$
(462
)
 
$
(214
)
Other comprehensive income (loss) before reclassification adjustments
   
4
     
(150
)
   
-
     
(808
)
   
(954
)
Amounts reclassified from accumulated OCI
   
-
     
(268
)
   
4
     
(2
)
   
(266
)
Tax benefit (provision)
   
-
     
159
     
(2
)
   
-
     
157
 
Net other comprehensive income (loss)
 
$
4
   
$
(259
)
 
$
2
   
$
(810
)
 
$
(1,063
)
Balance at May 31, 2016
 
$
33
   
$
-
   
$
(38
)
 
$
(1,272
)
 
$
(1,277
)

   
Pension/Post-
retirement
Obligations
   
Unrecognized
Gain
(Loss) on
Available-
for-Sale
Investments
   
Unrealized
Gain
(Loss) on
Cash Flow
Hedges
   
Share of
Alliance
Boots
OCI
   
Cumulative
Translation
Adjustments
   
Total
 
Balance at February 28, 2015
 
$
6
   
$
296
   
$
(39
)
 
$
-
   
$
(331
)
 
$
(68
)
Other comprehensive income (loss) before reclassification adjustments
   
(2
)
   
115
     
2
     
-
     
(145
)
   
(30
)
Amounts reclassified from accumulated OCI
   
-
     
-
     
(2
)
   
-
     
-
     
(2
)
Tax benefit (provision)
   
-
     
(41
)
   
-
     
-
     
-
     
(41
)
Net other comprehensive income (loss)
 
$
(2
)
 
$
74
   
$
-
   
$
-
   
$
(145
)
 
$
(73
)
Balance at May 31, 2015
 
$
4
   
$
370
   
$
(39
)
 
$
-
   
$
(476
)
 
$
(141
)

   
Pension/Post-
retirement
Liability
   
Unrecognized
Gain
(Loss) on
Available-
for-Sale
Investments
   
Unrealized
Gain
(Loss) on
Cash Flow
Hedges
   
Share of
Alliance
Boots
OCI
   
Cumulative
Translation
Adjustments
   
Total
 
Balance at August 31, 2014
 
$
15
   
$
107
   
$
(27
)
 
$
(113
)
 
$
154
   
$
136
 
Other comprehensive income (loss) before reclassification adjustments
   
(12
)
   
412
     
(16
)
   
(57
)
   
(793
)
   
(466
)
Amounts reclassified from accumulated OCI
   
-
     
-
     
(3
)
   
230
     
80
     
307
 
Tax benefit (provision)
   
1
     
(149
)
   
7
     
(60
)
   
83
     
(118
)
Net other comprehensive income (loss)
 
$
(11
)
 
$
263
   
$
(12
)
 
$
113
   
$
(630
)
 
$
(277
)
Balance at May 31, 2015
 
$
4
   
$
370
   
$
(39
)
 
$
-
   
$
(476
)
 
$
(141
)

Note 18. Segment Reporting
The Company has three reportable segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The operating segments have been identified based on the financial data utilized by the Company’s Chief Executive Officer (the chief operating decision maker) to assess segment performance and allocate resources among the Company’s operating segments, which have been aggregated as described below. The chief operating decision maker uses adjusted operating income to assess segment profitability. The chief operating decision maker does not use total assets by segment to make decisions regarding resources, therefore the total asset disclosure by segment has not been included.

· The Retail Pharmacy USA segment consists of the legacy Walgreens business, which includes the operation of retail drugstores and convenient care clinics and the provision of specialty pharmacy services. Revenues for the segment are principally derived from the sale of prescription drugs and a wide assortment of general merchandise, including non-prescription drugs, beauty products, photo finishing, seasonal merchandise, greeting cards and convenience foods.
 
· The Retail Pharmacy International segment consists primarily of the legacy Alliance Boots pharmacy-led health and beauty stores, optical practices, and related contract manufacturing operations. Stores are located in the United Kingdom, Mexico, Chile, Thailand, Norway, the Republic of Ireland, The Netherlands and Lithuania. Revenues for the segment are principally derived from the sale of prescription drugs and retail health, beauty, toiletries and other consumer products.

 
·
The Pharmaceutical Wholesale segment consists of the legacy Alliance Boots pharmaceutical wholesaling and distribution businesses and an equity method investment in AmerisourceBergen reported on a two-month lag. Wholesale operations are located in France, the United Kingdom, Germany, Turkey, Spain, The Netherlands, Egypt, Norway, Romania, Czech Republic and Lithuania. Revenues for the segment are principally derived from wholesaling and distribution of a comprehensive offering of brand-name pharmaceuticals (including specialty pharmaceutical products) and generic pharmaceuticals, health and beauty products, home healthcare supplies and equipment, and related services to pharmacies and other healthcare providers.
 
The results of operations for each reportable segment include synergy benefits, including WBAD operations and an allocation of corporate-related overhead costs. The “Eliminations and Unallocated Items” column contains items not allocable to the reportable segments, as the information is not utilized by the chief operating decision maker to assess segment performance and allocate resources.

The segment information reflects the operating results of the Company’s business segments. The Company began recording revenue and expense transactions using the new segments effective January 1, 2015. Beginning January 1, 2015, synergy benefits including WBAD operations have been allocated to the Retail Pharmacy USA, Retail Pharmacy International and Pharmaceutical Wholesale segments on a source of procurement benefit basis. Under this method, the synergy benefits are allocated to the segment whose purchase gave rise to the benefit. A synergy arising on the purchase of an item for use in an entity in the Retail Pharmacy USA segment is recognized in the Retail Pharmacy USA segment and similarly for the Retail Pharmacy International and Pharmaceutical Wholesale segments. Procurement service income related to third parties is recognized in the Pharmaceutical Wholesale segment. Corporate costs have been allocated to segments based on their respective gross profit.

The Company’s Retail Pharmacy International and Pharmaceutical Wholesale segments were acquired as part of the Second Step Transaction in which the Company acquired the 55% of Alliance Boots that it did not already own on December 31, 2014. The Company has determined that it is impracticable to restate segment information for periods prior the completion of the Second Step Transaction, as well as to provide disclosures for such periods under both the old basis and new basis of reporting for certain items. Specifically, WBAD operations prior to December 31, 2014 were recorded in the Retail Pharmacy USA segment and have not been restated, as the Company believes it is impracticable to separate the information to the individual reportable segments. Equity earnings from Alliance Boots prior to the completion of the Second Step Transaction has been recorded within the Retail Pharmacy USA segment. The equity earnings of the 45% interest in Alliance Boots have not been separated into the Retail Pharmacy International and Pharmaceutical Wholesale segments for the prior period, as the Company believes it is impracticable. Accordingly, only five months of results (January to May 2015) have been reported for these segments for the nine months ended May 31, 2015.

The following table reflects results of operations of the Company’s reportable segments (in millions):

   
Retail Pharmacy
                   
   
USA
   
International
   
Pharmaceutical
Wholesale
   
Eliminations
and
Unallocated
 Items
   
Consolidated
 
Three Months Ended
May 31, 2016
                             
Sales to external customers
 
$
21,185
   
$
3,132
   
$
5,181
   
$
-
   
$
29,498
 
Intersegment sales
   
-
     
62
     
567
     
(629
)
   
-
 
Total Sales
 
$
21,185
   
$
3,194
   
$
5,748
   
$
(629
)
 
$
29,498
 
                                         
Adjusted Operating Income
 
$
1,382
   
$
258
   
$
179
   
$
(5
)
 
$
1,814
 
                                         
 
Three Months Ended
May 31, 2015
                                       
Sales to external customers
 
$
20,425
   
$
3,231
   
$
5,139
   
$
-
   
$
28,795
 
Intersegment sales
   
-
     
37
     
569
     
(606
)
   
-
 
Total Sales
 
$
20,425
   
$
3,268
   
$
5,708
   
$
(606
)
 
$
28,795
 
                                         
Adjusted Operating Income
 
$
1,328
   
$
249
   
$
171
   
$
1
   
$
1,749
 
 
 
Retail Pharmacy
                   
   
USA
   
International
   
Pharmaceutical
 Wholesale
   
Eliminations
 and
Unallocated
Items
   
Consolidated
 
Nine Months Ended
May 31, 2016
                             
Sales to external customers
 
$
63,055
   
$
10,218
   
$
15,442
   
$
-
   
$
88,715
 
Intersegment sales
   
-
     
196
     
1,729
     
(1,925
)
   
-
 
Total Sales
 
$
63,055
   
$
10,414
   
$
17,171
   
$
(1,925
)
 
$
88,715
 
                                         
Adjusted Operating Income
 
$
4,257
   
$
908
   
$
500
   
$
(12
)
 
$
5,653
 
 
Nine Months Ended
May 31, 2015
                                       
Sales to external customers
 
$
61,027
   
$
5,248
   
$
8,647
   
$
-
   
$
74,922
 
Intersegment sales
   
-
     
67